Natera, BGI Genomics announce $50M partnership

Natera and BGI Genomics announced a $50M partnership to commercialize Natera’s Signatera MRD test in China, and to develop reproductive health tests in select markets on BGI’s sequencing instruments using the DNBseq NGS technology platform. The Natera Signatera MRD and molecular monitoring test will be offered in China, first through specialty hospital networks and then more broadly, once Natera and BGI Genomics gain China’s regulatory approval for use of the Signatera test on the DNBseq technology platform. DNBseq is the market name of BGI’s proprietary sequencing technology, which supports its portfolio of next-generation sequencing platforms. BGI Genomics’ genetic testing leadership position in China, where it performs over 1 million cell-free DNA tests annually, will accelerate Natera’s entry into this large and growing oncology market.
https://thefly.com/landingPageNews.php?id=2876941